Answers are grounded in this paper and cite their sources.
Dyslipidemia in patients with chronic kidney disease (CKD), particularly those on renal replacement therapy (RRT), is a major risk factor for cardiovascular complications. The pathogenesis of lipid metabolism disorders in this population is multifactorial and infl uenced by the underlying kidney disease, the specific characteristics of RRT, and, in transplant recipients, the effects of immunosuppressive therapy. Despite the high prevalence and clinical significance of dyslipidemia in CKD, therapeutic strategies for its correction remain insuffi ciently studied. This review analyzes current pharmacologic approaches to the management of dyslipidemia and evaluates the potential for their application in patients receiving RRT. Literature search was conducted using electronic databases Medline/PubMed (https://pubmed.ncbi.nlm.nih.gov) and eLIBRARY/Russian Science Citation Index (https://www.elibrary.ru).
No takes yet. Share an insight, caveat, or question.
Samburov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: